Wang Xiaoyu, Lin Yao, Li Zheng, Li Yueqi, Chen Mingcong
Biosafety Level-3 Laboratory, Life Sciences Institute & Guangxi Collaborative Innovation Center for Biomedicine, Guangxi Medical University, Nanning, Guangxi, China.
Department of Orthopedics and Traumatology, Shenzhen University General Hospital, Shenzhen, China.
Cancer Inform. 2024 Apr 12;23:11769351231180789. doi: 10.1177/11769351231180789. eCollection 2024.
Alternative polyadenylation (APA) plays a vital regulatory role in various diseases. It is widely accepted that APA is regulated by APA regulatory factors.
Whether APA regulatory factors affect the prognosis of renal cell carcinoma remains unclear, and this is the main topic of this study.
We downloaded the transcriptome and clinical data from The Cancer Genome Atlas (TCGA) database. We used the Lasso regression system to construct an APA model for analyzing the relationship between common APA regulatory factors and renal cell carcinoma. We also validated our APA model using independent GEO datasets (GSE29609, GSE76207).
It was found that the expression levels of 5 APA regulatory factors (CPSF1, CPSF2, CSTF2, PABPC1, and PABPC4) were significantly associated with tumor gene mutation burden (TMB) score in renal clear cell carcinoma, and the risk score constructed using the expression level of 5 key APA regulatory factors could be used to predict the outcome of renal clear cell carcinoma. The TMB score is associated with the remodeling of the immune microenvironment.
By identifying key APA regulatory factors in renal cell carcinoma and constructing risk scores for key APA regulatory factors, we showed that key APA regulators affect prognosis of renal clear cell carcinoma patients. In addition, the risk score level is associated with TMB, indicating that APA may affect the efficacy of immunotherapy through immune microenvironment-related genes. This helps us better understand the mRNA processing mechanism of renal clear cell carcinoma.
可变多聚腺苷酸化(APA)在多种疾病中发挥着至关重要的调节作用。人们普遍认为APA受APA调节因子的调控。
APA调节因子是否影响肾细胞癌的预后尚不清楚,这是本研究的主要课题。
我们从癌症基因组图谱(TCGA)数据库下载了转录组和临床数据。我们使用套索回归系统构建了一个APA模型,以分析常见APA调节因子与肾细胞癌之间的关系。我们还使用独立的GEO数据集(GSE29609、GSE76207)验证了我们的APA模型。
发现在肾透明细胞癌中,5种APA调节因子(CPSF1、CPSF2、CSTF2、PABPC1和PABPC4)的表达水平与肿瘤基因突变负担(TMB)评分显著相关,并且使用5个关键APA调节因子的表达水平构建的风险评分可用于预测肾透明细胞癌的预后。TMB评分与免疫微环境的重塑有关。
通过鉴定肾细胞癌中的关键APA调节因子并构建关键APA调节因子的风险评分,我们表明关键APA调节因子影响肾透明细胞癌患者的预后。此外,风险评分水平与TMB相关,表明APA可能通过免疫微环境相关基因影响免疫治疗的疗效。这有助于我们更好地理解肾透明细胞癌的mRNA加工机制。